Key portfolio assets

Compound Mechanism of action Target indication Status More Information

QUVIVIQ™   (daridorexant)

Dual orexin receptor antagonist

Insomnia

 Commercially available in the US, China, Hong-Kong, Japan, Canada, UK, Germany, Italy, Switzerland, Spain, France, Austria, Finland and Sweden; approved throughout the EU

Investor webcast

Lucerastat

Glucosylceramide synthase inhibitor

Fabry disease

 Regulatory pathway to registration agreed with the FDA and in line with the feedback received from the EMA. The program is on track to initiate in mid‑2026 and expected to support a potential regulatory filing as early as 2029  
Daridorexant Dual orexin receptor antagonist Pediatric insomnia Positive Phase 2 in pediatric insomnia – company to engage with health authorities to discuss next steps  
IDOR-1117-2520 CCR6 receptor antagonist Psoriasis Proof-of-concept study fully enrolled – readout expected in Q4 2026  

ACT-1004-1239

 CXCR7 / ACKR3 receptor antagonist Progressive multiple sclerosis Proof-of-concept study initiated – readout expected in Q2 2028  
ACT-777991 CXCR3 antagonist Vitiligo

Proof-of-concept study in preparation – initiation expected in Q2 2026, readout expected in 2027

  

 

Synthetic Glycan Vaccine Platform Idorsia will seek a partner for the platform or individual vaccines
IDOR-1134-2831 Synthetic glycan vaccine Clostridioides difficile infection Phase 1 data showing safety and immunogenicity – advanced to a higher-dose cohort, with top-line results anticipated in Q2 2026 – partnership discussions activated

For more information about our portfolio please read our Innovation fact sheet.

Partner-led portfolio

Compound Mechanism of action              Target indication

Partner: Terms

 Status
TRYVIO™
(aprocitentan)*		 Dual endothelin receptor antagonist Systemic hypertension in combination with other antihypertensives In partnership discussions: worldwide development and commercialization rights Commercially available in the US
JERAYGO™ (aprocitentan)* Dual endothelin receptor antagonist Resistant hypertension in combination with other antihypertensives In partnership discussions: worldwide development and commercialization rights Approved in the EU, UK, Switzerland, and Canada
QUVIVIQ™ 
(daridorexant)		 Dual orexin receptor 
antagonist		 Insomnia   Nxera Pharma: license to develop and commercialize 
for Asia-Pacific region (excluding China)		 Launched for the treatment of insomnia in Japan; Phase 3 successful in South Korea
QUVIVIQ™   (daridorexant) Dual orexin receptor 
antagonist		 Insomnia   Simcere: license to develop and commercialize
for the Greater China region		 Launched for the treatment of insomnia in China and Hong Kong

Selatogrel*

P2Y12 inhibitor              

Suspected acute myocardial infarction

Viatris: worldwide development and commercialization rights

Phase 3 “SOS-AMI” program ongoing

Cenerimod*

S1P1 receptor modulator   

Systemic lupus erythematosus    

Viatris: worldwide development and commercialization rights

 Phase 3 “OPUS” program ongoing

Daridorexant

Dual orexin receptor antagonist

 Posttraumatic stress
disorder (PTSD)

US Department of Defense (DOD):  Idorsia supports a clinical study sponsored
by the US DOD to develop new therapies to treat PTSD

 Phase 2 ongoing
ACT-1002-4391 EP2 / EP4 receptor antagonist Immuno-oncology Owkin: global license to develop and 
commercialize		 Phase 1 ongoing

 

* Idorsia has transferred its rights for aprocitentan, cenerimod, and selatogrel to Idorsia Investments SARL to allow the repayment of notes issued in connection with the repurchase offer completed in August 2025. More details on the transfer can be found in the press release issued on May 21, 2025 and on the exchange offer in the press release issued on August 27, 2025.